



<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/687,118
PTO FORM 1449		APPLICANT Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP <u>1644</u> Not yet assigned

<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	1.	6,329,511	12/11/2001	Landolfi Nicholas F., et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
C.C.	2.	PCT/US2004/011213 (Search Report)	12/10/2004	PCT			
<b>OTHER REFERENCES</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
C.C.	3.	He X-y, et al.; "Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-selectin" The American Association of Immunologists; 1998					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*C.C. 12/19/05*



Sheet 1 of 1

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i> <b>PTO FORM 1449</b>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/687,118
		APPLICANT Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP -4645- 1644

<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	1.	6,277,375	08/21/01	Ward			
<b>FOREIGN PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
C.C.	2.	Int'l Search Report	05/04/05	PCT			YES NO
<b>OTHER REFERENCES</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
C.C.	3.	Chintalacharuvu, et al., "Hybrid IgA2/IgG1 Antibodies with Tailor-Made Effector Functions", <i>Clin. Imm.</i> 101(1):21-31 (2001)					
	4.						
	5.						
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						
	17.						
	18.						
	19.						
	20.						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Ch. ey* 12/9/05



<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/687,118
PTO FORM 1449		APPLICANT	
		Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP <u>1644</u> Not yet assigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	1.	5,994,514	08/14/91				
	2.	20010033842A1	08/14/91				
	3.	6,165,745	04/24/92				
	4.	20030044858A1	05/07/92				
	5.	20030003098A1	04/05/95				
	6.	20020098193A1	03/03/97				
	7.	6,277,375	08/21/01				
	8.	6,528,624	03/04/03				
	9.	5,530,101	06/25/96				
C.C.	10.	5,834,597	11/10/98				

FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES	NO	
C.C.	11.	WO9304173A1	08/14/91	PCT			
	12.	EP1260521A2	08/14/91	Europe			
	13.	WO9631229A1	04/05/95	PCT			
	14.	WO9728267A1	02/02/96	PCT			
	15.	WO9734631A1	03/18/96	PCT			
	16.	WO9805787A1	08/02/96	PCT			
	17.	WO9847531A2	04/21/97	PCT			
	18.	WO0047625A2	02/12/99	PCT			
	19.	WO0158957A2	02/11/00	PCT			
	20.	WO0260919A2	12/12/00	PCT			
	21.	WO9902709A1	07/10/97	PCT			
C.C.	22.	WO0042072A2	01/15/99	PCT			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Ch. es 12/19/05*

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/687,118
<b>PTO FORM 1449</b>		APPLICANT	
		Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP <u>16</u> Not yet assigned

<u>C.C.</u>	23.	WO9734621A1	09/25/97	PCT		
	24.	WO9958572A1	11/18/99	PCT		
	25.	WO9823289A1	06/04/98	PCT		
<u>C.C.</u>	26.	WO9951642	10/14/99	PCT		

**OTHER REFERENCES**  
*(Including Author, Title, Date, Pertinent Pages, Etc.)*

<u>C.C.</u>	27.	Achazt, et al., "The IgE Antigen Receptor: a Key Regulator for the Production of IgE Antibodies." <i>Int. Arch. Allergy Immunol.</i> 124(1-3): 31-4 (2001)
	28.	Alegre, et al., "Effect of a single amino acid mutation on the activating and immunosuppressive properties of a humanized OKT3 monoclonal antibody." <i>J. Immunol.</i> 148(11):3461-8 (1992)
	29.	Angal, et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody." <i>Mol Immunol.</i> 30(1): 105-8 (1993)
	30.	Armour, et al., "Recombinant human IgG molecules lacking Fc <sub>gamma</sub> receptor I binding and monocyte triggering activities," <i>Eur J Immunol.</i> 29(8): 2613-24 (1999)
	31.	Armour, et al., "The Contrasting IgG-Binding Interactions of Human and Herpes Simplex Virus Fc Receptors," <i>Biochem Soc. Trans.</i> , 30(4): 495-500 (2002)
	32.	Arya, et al. "Mapping of amino acid residues in the C mu 3 domain of mouse IgM important in macromolecular assembly and complement-dependent cytosis," <i>J Immunol</i> 152(3): 1206-12 (1994)
	33.	Batra, et al., "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life." <i>Molec. Immunol.</i> 30(4), 379-386 (1993).
	34.	Brekke, et al., "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis." <i>Eur J Immunol</i> 24(10): 2542-7 (1994)
	35.	Burmeister et al., "Crystal structure of the complex of rat neonatal Fc receptor with Fc," <i>Nature</i> 372:379-383 (1994).
	36.	Canfield, "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region," <i>J Exp Med</i> 173(6): 1483-91 (1991)
	37.	Caron, et al., "Engineered humanized dimeric forms of IgG are more effective antibodies," <i>J Exp Med</i> 176(4): 1191-5 (1992)
	38.	Chapman, et al., "Characterization of the Interaction Between the Herpes Simplex Virus Type 1 Fc Receptor and Immunoglobulin G." <i>J. Biol. Chem.</i> 274(11): 6911-9 (1999)
<u>C.C.</u>	39.	Chappel, et al., "Identification of a secondary Fc gamma RI binding site within a genetically

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CL OF 12/19/05

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/587,118
<b>PTO FORM 1449</b>		APPLICANT Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP <u>1644</u> Not yet assigned

		engineered human IgG antibody," <i>J Biol Chem</i> 268(33): 25124-31 (1993)
<u>C. C.</u>	40.	Chaudhury <i>et al.</i> , "The Major Histocompatibility Complex-related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan," <i>J. Exp. Med.</i> 197(3), 315-322 (Feb. 3, 2003).
	41.	Cole, <i>et al.</i> , "Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells," <i>J Immunol</i> 159(7): 3613-21 (1997)
	42.	Cole, <i>et al.</i> , "HuM291, A Humanized Anti-CD3 Antibody, is Immunosuppressive to T Cells While Exhibiting Reduced Mitogenicity in Vitro," <i>Transplantation</i> , 68(4): 563-71 (1999)
	43.	Dall'Acqua, <i>et al.</i> , "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences," <i>J. Immunol.</i> 169(9): 5171-80 (2002)
	44.	Deisenhofer, "Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from <i>Staphylococcus aureus</i> at 2.9- and 2.8-A resolution," <i>Biochemistry</i> 20:2361-2370 (1981)
	45.	Delano, <i>et al.</i> , "Convergent Solutions to Binding at a Protein-Protein Interface," <i>Science</i> , 287(5456): 1279-83 (2000)
	46.	Dorai, <i>et al.</i> , "Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1," <i>Mol Immunol</i> 29(12): 1487-91 (1992)
	47.	Duncan, <i>et al.</i> , "The binding site for C1q on IgG," <i>Nature</i> 332(6166): 738-40 (1988)
	48.	Ehrlich <i>et al.</i> , "Characterization of human monoclonal antibodies directed against hepatitis B surface antigen," <i>Hum. Antibodies Hybridomas</i> 3:2-7 (1992)
	49.	El-Amine, <i>et al.</i> , "In Vivo Induction of Tolerance by an Ig Peptide is not Affected by the Deletion of FcR or a Mutated IgG Fc Fragment," <i>Int. Immunol.</i> , 14(7): 761-6 (2002)
	50.	Firan, <i>et al.</i> , "The MHC Class I-Related Receptor FcRn, Plays an Essential Role in the Maternofetal Transfer of Gamma-Globulin in Humans," <i>Int. Immunol.</i> , 13(8): 993-1002 (2001)
	51.	Ghetie and Ward, "Multiple roles for the major histocompatibility complex class I-related receptor FcRn," <i>Annu. Rev. Immunol.</i> 18:739-766 (2000)
	52.	Ghetie <i>et al.</i> , "Increasing the serum persistence of an IgG fragment by random mutagenesis," <i>Nat. Biotechnol.</i> 15:637-640 (1997)
	53.	Heilm, <i>et al.</i> , "Identification of the high affinity receptor binding region in human immunoglobulin E," <i>J Biol Chem</i> 271(13): 7494-500 (1996)
	54.	Hezareh, <i>et al.</i> , "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type," <i>J. Virol.</i> , 75(24): 12161-8 (2001)
	55.	Hinton <i>et al.</i> , "Engineered Human IgG Antibodies with Longer Serum Half-lives in Primate," <i>J. Biol. Chem.</i> 279(8) 6213-6216 (2004).
<u>C. C.</u>	56.	Homick, <i>et al.</i> , "Single Amino Acid Substitution in the Fc Region of Chimeric TNT-3 Antibody Accelerates Clearance and Improves Immunoscintigraphy of Solid Tumors," <i>J. Nucl. Med.</i> 41(2):

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*C. C. of 12/9/05*

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO.	APPLICATION NO.
		05882.0039.NPUS04	10/587,118
		APPLICANT	
		Paul R. Hinton, et al.	
		FILING DATE	GROUP <u>1640</u>
		10/15/03	Not yet assigned

		355-62 (2000)
<u>C. C.</u>	57.	Isaacs, et al., "Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function," <i>J Immunol</i> 161(8): 3862-9 (1998)
	58.	Ito, et al., "[An amino acid substitution determining G1m(x) allotypic marker]," <i>Nippon Hoigaku Zasshi</i> 43(2): 155-60 (1989)
	59.	Jendeberg, et al., "Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A," <i>J Immunol Methods</i> 201(1): 25-34 (1997)
	60.	Jollife, "Humanized antibodies: enhancing therapeutic utility through antibody engineering," <i>Int Rev Immunol</i> 10(2-3): 241-50 (1993)
	61.	Kim et al., "Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn," <i>Eur. J. Immunol.</i> 29:2819-2825 (1999).
	62.	Kim et al., "Catabolism of the Murine IgG1 Molecule: Evidence that Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice," <i>Scand. J. Immunol.</i> 40, 457-465 (1994)
	63.	Kim, et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor," <i>Eur J Immunol</i> 24(10): 2429-34 (1994)
	64.	Kostelný et al., "Humanization and characterization of the anti-HLA-DR antibody 1D10," <i>Int. J. Cancer</i> 93:556-565 (2001)
	65.	Lund, et al., "Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG," <i>J Immunol</i> 147(8): 2657-62 (1991)
	66.	Lund, et al., "Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma RII," <i>Mol Immunol</i> 29(1): 53-9 (1992)
	67.	Lund, et al., "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains," <i>J Immunol</i> 157(11): 4963-9 (1996)
	68.	Martin et al., "Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding," <i>Mol. Cell</i> 7:867-877 (2001)
	69.	Martin, W.L. "Protein-Protein Recognition: The Neonatal Fc Receptor and Immunoglobulin G," Doctoral dissertation, California Institute of Technology (2001)
	70.	McDonnell, et al., "The Structure of the IgE Cepsilon2 Domain and its Role in Stabilizing the Complex with its High-Affinity Receptor FepsilonR1alpha," <i>Nat. Struc. Biol.</i> , 8(5): 437-41 (2001)
	71.	Medesan et al., "Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site," <i>Eur. J. Immunol.</i> , 28:2092-2100 (1998)
<u>C. C.</u>	72.	Medesan, et al., "Delineation of the amino acid residues involved in transcytosis and catabolism of

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Ch CS 12/9/05*

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO. 05882.0039.NPUS04	APPLICATION NO. 10/687,118
PTO FORM 1449		APPLICANT Paul R. Hinton, et al.	
		FILING DATE 10/15/03	GROUP <u>1644</u> Not yet assigned

		mouse IgG1,* <i>J Immunol</i> 158(5): 2211-7 (1997)
<u>C.C.</u>	73.	Morison, et al., "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk," <i>Mol. Immunol</i> 38(8): 619-25 (2002)
	74.	Muraoka, "Structural requirements for IgM assembly and cytolytic activity. Effects of mutations in the oligosaccharide acceptor site at Asn402," <i>J Immunol</i> 142(2): 695-701 (1989)
	75.	Nagaoka, et al., "Single Amino Acid Substitution in the Mouse IgG1 Fc region induces drastic enhancement of the Affinity to Protein A," <i>Protein Eng.</i> , 16(4): 243-5 (2003)
	76.	Newman, et al., "Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors But Does Not Deplete CD4(+) T Cells in Chimpanzees," <i>Clin. Immunol.</i> 98(2): 164-74 (2001)
	77.	Popov, et al., "The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn," <i>Mol Immunol</i> 33(6): 521-30 (1996)
	78.	Radaev, et al., "Recognition of Immunoglobulins by Fc gamma Receptors," <i>Mol. Immunol.</i> 38(14): 1073-83 (2001)
	79.	Raghavan et al., "Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand," <i>Immunity</i> 1:303-315 (1994)
	80.	Raghavan, et al., "Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants," <i>Biochemistry</i> 34(45): 14649-57 (1995)
	81.	Saper et al., "Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution," <i>J. Mol. Biol.</i> 219:277-319 (1991)
	82.	Sarmay, et al., "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor," <i>Mol Immunol</i> 29(5): 633-9 (1992)
	83.	Shields et al., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R," <i>J. Biol. Chem.</i> 276:6591-6604 (2001)
	84.	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>J Immunol</i> 148(9): 2918-22 (1992)
	85.	Simister and Mostov, "An Fc receptor structurally related to MHC class I antigens," <i>Nature</i> 337:184-187 (1989)
	86.	Tao, "Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region," <i>J Immunol</i> 143(8): 2595-601 (1989)
<u>C.C.</u>	87.	Taylor, et al., "In Vitro and in Vivo Activities of OX40 (CD134)-IgG Fusion Protein Isoforms with Different Levels of Immune-Effector Functions," <i>J. Leukoc. Biol.</i> , 72(3): 522-9 (2002)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

On 04 12/9/05

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	APPLICATION NO.
		05882.0039.NPUS04	10/687,118
		APPLICANT	
		Paul R. Hinton, et al.	
		FILING DATE	GROUP <i>1644</i>
		10/15/03	<i>Not yet assigned</i>

<i>C.C</i>	88.	Ward and Ghetie, "The effector functions of immunoglobulins: implications for therapy," <i>Ther. Immunol.</i> 2:77-94 (1995)
<i>C</i>	89.	Ward et al., "Evidence to Support the Cellular Mechanism Involved in Serum IgG Homeostasis in Humans," <i>Int'l Immunol.</i> 15(2), 187-195 (2003).
<i>C</i>	90.	Wawrzynczak, et al., "Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting C1q and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse," <i>Mol Immunol</i> 29(2): 221-7 (1992)
<i>C</i>	91.	Weng et al., "Computational determination of the structure of rat Fc bound to the neonatal Fc receptor," <i>J. Mol. Biol.</i> 282:217-225 (1998)
<i>C.C</i>	92.	West and Bjorkman, "Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor," <i>Biochemistry</i> 29:9698-9708 (2000)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*er es 12/9/05*